Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”
Tài liệu tham khảo
Pappagallo M, Inturrisi C, Manfredi P. Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.” CNS Drugs. 2021. https://doi.org/10.1007/s40263-021-00891-0.
Henter ID, Park LT, Zarate CAJ. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35:527–43. https://doi.org/10.1007/s40263-021-00816-x.
US Drug Enforcement Administration. Drug and Chemical Information Section: Methadone. Springfield, VA, US Drug Enforcement Administration, Diversion, Control Division. 2019. https://www.deadiversion.usdoj.gov/drug_chem_info/methadone/methadone.pdf.
Moryl N, Tamasdan C, Tarcatu D, Thaler HT, Correa D, Steingart R, et al. A phase I study of D-methadone in patients with chronic pain. J Opioid Manag. 2016;12:47–55.
Hagler G. BioSpace: Relmada Therapeutics developing REL-1017 to treat major depression. April 21, 2020. 2020 [cited 2020. https://www.biospace.com/article/relmada-developing-rel-1017-to-treat-major-depression/. Accessed 21 Sept 2020.
Relmada Therapeutics I. Relmada Therapeutics announces top-line results from REL-1017 Phase 2 study in individual with treatment resistant deprssion. October 15, 2019. 2019 [cited 2019. https://www.prnewswire.com/news-releases/relmada-therapeutics-announces-top-line-results-from-rel-1017-phase-2-study-in-individuals-with-treatment-resistant-depression-300938577.html. Accessed 21 Sept 2020.